JASBIR SAINI, M.D.; MICHAEL W. RICH, M.D.; ALAN P. LYSS, M.D.
Doxorubicin is a potent anticancer agent effective in a wide range of malignancies, but its use is limited by dose-dependent late cardiotoxicity. Severe doxorubicin cardiotoxicity has been associated with a poor prognosis and a high mortality rate, and until recently has been thought to be irreversible. We describe the cases of three patients with well-documented severe left ventricular dysfunction due to doxorubicin who had complete clinical recovery with return of cardiac function to normal. Because severe doxorubicin cardiotoxicity is reversible in some patients, aggressive supportive therapy is warranted.
Learn more about subscription options.
Register Now for a free account.
SAINI J, RICH MW, LYSS AP. Reversibility of Severe Left Ventricular Dysfunction Due to Doxorubicin Cardiotoxicity: Report of Three Cases. Ann Intern Med. 1987;106:814-816. doi: 10.7326/0003-4819-106-6-814
Download citation file:
Published: Ann Intern Med. 1987;106(6):814-816.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only